title: Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives.
abstract: Diabetic nephropathy (DN) is one of the most common complications of diabetes with high mortality rates worldwide. The treatment of DN has posed a formidable challenge to the scientific community. Simple control of risk factors has been insufficient to cope with the progression of DN. During the process of anti-DN drug discovery, multiple pathogeneses such as oxidative stress, inflammation and fibrosis should all be considered. In this review, the pathogenesis of DN is summarized. The major context focuses on a few small molecules toward the pathogenesis available in animal models and clinical trials for the treatment of DN. The perspectives of novel anti-DN agents and the future directions for the prevention of DN are discussed.
authors.affiliation: Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Central South University, 410013 Changsha, Hunan, China.
authors.forename: Meng
authors.initials: M
authors.lastname: Lv
authors.affiliation: Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Central South University, 410013 Changsha, Hunan, China.
authors.forename: Zhuo
authors.initials: Z
authors.lastname: Chen
authors.affiliation: Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Central South University, 410013 Changsha, Hunan, China. Electronic address: hugaoyun@csu.edu.cn.
authors.forename: Gaoyun
authors.initials: G
authors.lastname: Hu
authors.affiliation: Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Central South University, 410013 Changsha, Hunan, China. Electronic address: qbli@csu.edu.cn.
authors.forename: Qianbin
authors.initials: Q
authors.lastname: Li
mesh_terms: D000818:Animals; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000378:metabolism; D055808:Drug Discovery; D005355:Fibrosis / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy; D064546:Protein Kinase C beta / Q000378:metabolism; D012307:Risk Factors
chemical_list: D007004:Hypoglycemic Agents; D064546:Protein Kinase C beta